Linnet K, et al. - In this longitudinal cohort study done in primary healthcare in the Reykjavik area, 114,084 people contacting general practitioners during 2009–2012 were recruited by investigators to evaluate the risk of mortality in primary care patients, multimorbid (≥ 2 chronic conditions) or not, prescribed hypnotics/anxiolytics. Among both multimorbid and non-multimorbid individuals taking hypnotics/anxiolytics, mortality rose in a dose-dependent manner. This rise was clearly related to the prescription of these drugs. Thus, their use should be restricted to the suggested period of 2–4 weeks, up to 6 weeks. Moreover, long-term use could provoke heightened risk and should be re-examined, noted the investigators.